Therapeutic consequences for misdiagnosis of Type 2N von Willebrand disease

Pediatric Blood and Cancer

Volumn 57, Issue 6, 2011, Pages 1081-1083

  Gupta, Madhu ^a   Lillicrap, David ^b   Stain, Ann Marie ^a   Friedman, Kenneth D ^c   Carcao, Manuel D ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Children; Misdiagnosis; Treatment; Type 2N von Willebrand disease

Indexed keywords

DESMOPRESSIN; RECOMBINANT THROMBOPLASTIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

ARTICLE; AVASCULAR NECROSIS; BLOOD ANALYSIS; BONE SCINTISCANNING; CASE REPORT; CHILD; DIAGNOSTIC ERROR; DISEASE SEVERITY; ECHOGRAPHY; EPISTAXIS; FEMALE; FEMUR HEAD; GENE MUTATION; GENETIC SCREENING; HEAD INJURY; HEMARTHROSIS; HEMOPHILIA A; HIP PAIN; HUMAN; MALE; MUSCLE BLEEDING; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT FAILURE; VON WILLEBRAND DISEASE;

CHILD; CHILD, PRESCHOOL; FACTOR VIII; FEMALE; HUMANS; MALE; RECOMBINANT PROTEINS; VON WILLEBRAND DISEASE, TYPE 2;

EID: 80052680438     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23120     Document Type: Article

References (17)

1. Fay PJ, Coumans JV, Walker FJ. Von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266: 2172-2177.
2. Plantier JL, Rolli V, Ducasse C, et al. Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency. J Thromb Haemost 2009; 8: 286-293.
3. Mazurier C, Dieval J, Jorieux S, et al. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Thromb Haemost 1990; 75: 20-26.
4. Nishino M, Girma JP, Rothschild C, et al. New variant of von Willebrand disease with defective binding to Factor VIII. Blood 1989; 74: 1591-1599.
5. Mazurier C, Goudemand J, Hilbert L, et al. Type 2N von Willebrand disease: Clinical manifestations, pathophysiology, laboratory diagnosis, and molecular biology. Best Practice Res Clin Hemat 2001; 14: 337-347.
6. Schneppenheim R, Budde U, Krey S, et al. Results of a screening for von Willebrand disease type 2N in patients with suspected Haemophilia A or von Willebrand disease type 1. Thromb Haemost 1996; 76: 598-602.
7. Mazurier C, Gaucher C, Jorieux S, et al. Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophila A carriers: Consequences for therapy and genetic counselling. Br J Haematol 1990; 76: 372-379.
8. Nesbitt IM, Goodeve AC, Guilliatt AM, et al. Characterisation of type 2N von Willebrand disease using phenotypic and molecular techniques. Thromb Haemost 1996; 75: 959-964.
9. Tuley EA, Gaucher C, Jorieux S, et al. Expression of von Willebrand factor "Normandy": An autosomal mutation that mimics Hemophilia A. Proc Nat Acad Sci USA 1991; 88: 6377-6381.
10. Mazurier C. von Willebrand disease masquerading as Haemophilia A. Thromb Haemost 1991; 67: 391-396.
11. Canadian Hemophilia Registry. Association of Hemophilia Clinic Directors of Canada. Available at (accessed July, 2010).
12. Eikenboom JC, Reitsma PH, Peerlinck KMJ, et al. Recessive inheritance of von Willebrand's disease type 1. Lancet 1993; 341: 982-986.
13. Bowen DJ, Standen GR, Mazurier C, et al. Type 2N von Willebrand disease: Rapid genetic diagnosis of G2811A (R854Q), C2696T (R816W), T2701A (H817Q) and G2823T (C858F)-Detection of a novel candidate type 2N mutation: C2810T (R854W). Thromb Haemost 1998; 80: 32-36.
14. Jorieux S, Tuley EA, Gaucher C, et al. The mutation Arg(53)→Trp causes von Willebrand Disease Normandy by abolishing binding to Factor VIII. Studies with recombinant von Willebrand factor. Blood 1992; 79: 563-567.
15. Mazurier C, Gaucher C, Jorieux S, et al. Biological effect of desmopressin in eight patients with type 2N ('Normandy') von Willebrand disease. Br J Haematol 1994; 88: 849-854.
16. Casonato A, Pontara E, Sartorello F, et al. Identifying carriers of type 2N von Willebrand disease: Procedures and significance. Clin Appl Thromb Haemost 2007; 13: 194-200.
17. Hilbert L, Nurden P, Caron C, et al. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide. Thromb Haemost 2006; 96: 290-294.